Losartan potassium is a medication that is commonly used to treat high blood pressure. It is an effective medication that can help to lower blood pressure and reduce the risk of cardiovascular disease. It is an orally active, nonpeptide angiotensin II receptor antagonist. Losartan potassium has low bioavailability and the risk of first-pass metabolism. To overcome these limitations, the formulation of Losartan Potassium as a fast-dissolving tablet using co-processed excipients and super disintegrants is explored. The goal was to promote faster disintegration and better hardness. Four different co-processed excipients were tested for flow properties, and tablets were prepared using the direct compression method. The tablets prepared with Disintequik ODT showed the best flow properties and fastest disintegration time compared to other co-processed excipients. Central Composite Design response surface methodology was used to optimize the formulation of the tablets. The study focused on two independent variables: X1 (amount of co-processed excipient) and X2 (amount of super disintegrant). Two responses were measured: Y1 (Hardness) and Y2 (Disintegration time). All formulations showed notably faster disintegration and better hardness. The co-processed excipient Disintequik ODT and super disintegrant Sodium starch glycolate were used. A response surface plot was created to graphically represent the effect of independent variables on disintegration time and hardness. The concentration of co-processed excipients and super disintegrant was optimized for a disintegration time of 25 seconds. Invitro drug release for optimised formulation is 99.02%. The optimized formulation was compared with a marketed product. Finally, short-term stability studies were conducted, which indicated that there was no significant change in disintegration time and drug content.